Literature DB >> 7537727

Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection of the killer cells with the gamma-interferon gene.

M Mizuno1, J Yoshida, T Takaoka, K Sugita.   

Abstract

Lymphokine-activated killer (LAK) cells generated from peripheral blood lymphocytes incubated with recombinant interleukin-2 were transfected with the human gamma-interferon (HuIFN-gamma) gene by means of liposomes having a positive charge on their surface. The cells secreted significant amounts of HuIFN-gamma (reaching more than 5 U/ml) into the culture medium. The HuIFN-gamma produced by the cells induced intercellular adhesion molecule-1 (ICAM-1) and enhanced the expression of Fas antigen on the surface of human glioma cells. Also, LAK cells transfected with HuIFN-gamma gene exhibited reinforcement of cytotoxicity toward human glioma cell lines (U251-MG and SK-MG-1). Furthermore, the reinforcement was significantly quenched by anti-ICAM-1 and/or anti-TNF-alpha monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537727      PMCID: PMC5920590          DOI: 10.1111/j.1349-7006.1995.tb02993.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  18 in total

1.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).

Authors:  S D Marlin; T A Springer
Journal:  Cell       Date:  1987-12-04       Impact factor: 41.582

2.  Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas.

Authors:  M C Kuppner; M F Hamou; N de Tribolet
Journal:  J Neuroimmunol       Date:  1990 Sep-Oct       Impact factor: 3.478

3.  Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas.

Authors:  P Möller; C Henne; F Leithäuser; A Eichelmann; A Schmidt; S Brüderlein; J Dhein; P H Krammer
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

4.  Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring.

Authors:  F Farace; M Pallardy; E Angevin; T Hercend; B Escudier; F Triebel
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

5.  Modulation of associated ovarian carcinoma antigens by 5 cytokines used as single agents or in combination.

Authors:  B M Imbert-Marcille; P Thédrez; C Saï-Maurel; C François; J L Auget; J Benard; Y Jacques; S Imai; J F Chatal
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

6.  Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.

Authors:  R S Cotran; J S Pober; M A Gimbrone; T A Springer; E A Wiebke; A A Gaspari; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

7.  Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor.

Authors:  C E Griffiths; J J Voorhees; B J Nickoloff
Journal:  J Am Acad Dermatol       Date:  1989-04       Impact factor: 11.527

8.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

Authors:  D Barba; S C Saris; C Holder; S A Rosenberg; E H Oldfield
Journal:  J Neurosurg       Date:  1989-02       Impact factor: 5.115

9.  Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.

Authors:  S C Campbell; K Tanabe; J P Alexander; M Edinger; R R Tubbs; E A Klein
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

10.  The amino acid sequences of the myelin-associated glycoproteins: homology to the immunoglobulin gene superfamily.

Authors:  J L Salzer; W P Holmes; D R Colman
Journal:  J Cell Biol       Date:  1987-04       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.